


Ligustroflavone

Cat. No.:	HY-N0546
CAS No.:	260413-62-5
Molecular Formula:	C ₃₃ H ₄₀ O ₁₈
Molecular Weight:	724.66
Target:	CaSR
Pathway:	GPCR/G Protein
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (172.49 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	1.3800 mL	6.8998 mL	13.7996 mL
5 mM		0.2760 mL	1.3800 mL	2.7599 mL	
	10 mM	0.1380 mL	0.6900 mL	1.3800 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<p>1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.87 mM); Clear solution</p> <p>2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.87 mM); Clear solution</p>				

BIOLOGICAL ACTIVITY

Description	Ligustroflavone, extracted from <i>Ligustrum lucidum</i> , is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice ^[1] .
IC ₅₀ & Target	CaSR ^[1] .

REFERENCES

[1]. Feng R, et al. Protective Effects of Ligustroflavone, an Active Compound from *Ligustrum lucidum*, on Diabetes-Induced Osteoporosis in Mice: A Potential Candidate as Calcium-Sensing Receptor Antagonist. *Am J Chin Med.* 2019;47(2):457-476.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA